Vaccine-maker Bharat Biotech claimed that with several hundred million doses administered worldwide, Covaxin has demonstrated an excellent safety record with minimal adverse events and no vaccine associated cases detected for myocarditis or thrombocytopenia
Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world’s third worst-hit nation.
ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.
In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.
On Sept. 3, 2025, China celebrated the 80th anniversary of its victory over Japan by staging a carefully choreographed event…
Since August 20, Jammu and Kashmir has been lashed by intermittent rainfall. Flash floods and landslides in the Jammu region…
The social, economic and cultural importance of the khejri tree in the Thar desert has earned it the title of…
On Thursday, 11 September, the Congress party launched a sharp critique of Prime Minister Narendra Modi’s recent tribute to Rashtriya…
Solar panels provide reliable power supply to Assam’s island schools where grid power is hard to reach. With the help…
August was a particularly difficult month for the Indian Himalayan states of Uttarakhand, Himachal Pradesh and Jammu and Kashmir. Multiple…
This website uses cookies.